MA37317B1 - Formulation d'anticorps il-17 - Google Patents

Formulation d'anticorps il-17

Info

Publication number
MA37317B1
MA37317B1 MA37317A MA37317A MA37317B1 MA 37317 B1 MA37317 B1 MA 37317B1 MA 37317 A MA37317 A MA 37317A MA 37317 A MA37317 A MA 37317A MA 37317 B1 MA37317 B1 MA 37317B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
stabilized
polysorbate
psoriasis
citrate
Prior art date
Application number
MA37317A
Other languages
English (en)
Other versions
MA37317A1 (fr
Inventor
Vincent John Corvari
Barbara Ann Williams
Patrick Daniel Donovan
Aaron Paul Markham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA37317A1 publication Critical patent/MA37317A1/fr
Publication of MA37317B1 publication Critical patent/MA37317B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques stabilisées pour anticorps anti-il -17, comprenant par exemple du citrate, du chlorure de sodium et du polysorbate -80 à un ph de 5,7. Ces formulations pharmaceutiques stabilisées pour anticorps anti-il -17 peuvent être utilisées pour traiter l'arthrite rhumatoïde, le psoriasis, la spondylite ankylosante, l'arthrite psoriasique ou le myélome multiple.
MA37317A 2012-03-07 2014-09-02 Formulation d'anticorps il-17 MA37317B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607671P 2012-03-07 2012-03-07
PCT/US2013/028516 WO2013134052A1 (fr) 2012-03-07 2013-03-01 Formulation d'anticorps il-17

Publications (2)

Publication Number Publication Date
MA37317A1 MA37317A1 (fr) 2016-03-31
MA37317B1 true MA37317B1 (fr) 2016-10-31

Family

ID=47892018

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37317A MA37317B1 (fr) 2012-03-07 2014-09-02 Formulation d'anticorps il-17

Country Status (34)

Country Link
US (3) US9376491B2 (fr)
EP (2) EP2822590B1 (fr)
JP (1) JP6117252B2 (fr)
KR (1) KR101653082B1 (fr)
CN (1) CN104159612B (fr)
AU (1) AU2013230490B2 (fr)
BR (1) BR112014021308B1 (fr)
CA (1) CA2866128C (fr)
CL (1) CL2014002204A1 (fr)
CY (1) CY1118393T1 (fr)
DK (1) DK2822590T3 (fr)
EA (1) EA030742B1 (fr)
EC (1) ECSP14017562A (fr)
ES (1) ES2610707T3 (fr)
HR (1) HRP20161604T1 (fr)
HU (1) HUE031290T2 (fr)
IL (1) IL234053B (fr)
LT (1) LT2822590T (fr)
MA (1) MA37317B1 (fr)
ME (1) ME02565B (fr)
MX (1) MX362191B (fr)
MY (1) MY167233A (fr)
NZ (1) NZ627648A (fr)
PE (1) PE20142275A1 (fr)
PH (1) PH12014501985A1 (fr)
PL (1) PL2822590T3 (fr)
PT (1) PT2822590T (fr)
RS (1) RS55417B1 (fr)
SG (1) SG11201404491XA (fr)
SI (1) SI2822590T1 (fr)
TN (1) TN2014000341A1 (fr)
UA (1) UA114620C2 (fr)
WO (1) WO2013134052A1 (fr)
ZA (1) ZA201405654B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
WO2019027828A1 (fr) * 2017-08-04 2019-02-07 Eli Lilly And Company Schéma posologique d'anticorps anti-il-17
EP3672988A1 (fr) 2017-08-23 2020-07-01 Eli Lilly and Company Traitement du psoriasis génital
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN112915201B (zh) * 2019-12-06 2023-06-27 珠海市丽珠单抗生物技术有限公司 包含抗il-17抗体的液体制剂
WO2022135395A1 (fr) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 Préparation d'anticorps stable, son procédé de préparation et ses applications
CN119147687B (zh) * 2024-11-11 2025-03-14 智翔（上海）医药科技有限公司 用于抗白介素17a抗体质量检测的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101326195B9 (zh) * 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
CN101557799B (zh) * 2006-12-05 2012-08-22 克鲁塞尔荷兰公司 液体抗狂犬病抗体制剂
HRP20171939T1 (hr) * 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije

Also Published As

Publication number Publication date
MX362191B (es) 2019-01-08
DK2822590T3 (en) 2017-01-23
US20150010573A1 (en) 2015-01-08
PH12014501985B1 (en) 2014-11-24
PT2822590T (pt) 2016-12-15
US10472416B2 (en) 2019-11-12
ZA201405654B (en) 2016-05-25
SI2822590T1 (sl) 2017-01-31
CL2014002204A1 (es) 2015-01-30
PH12014501985A1 (en) 2014-11-24
EA201491471A1 (ru) 2014-12-30
JP6117252B2 (ja) 2017-04-19
IL234053B (en) 2018-06-28
ME02565B (fr) 2017-02-20
AU2013230490B2 (en) 2017-04-13
WO2013134052A1 (fr) 2013-09-12
CA2866128A1 (fr) 2013-09-12
NZ627648A (en) 2016-10-28
ES2610707T3 (es) 2017-05-03
MY167233A (en) 2018-08-14
US20160280781A1 (en) 2016-09-29
UA114620C2 (uk) 2017-07-10
HRP20161604T1 (hr) 2016-12-30
HUE031290T2 (hu) 2017-06-28
ECSP14017562A (es) 2015-09-30
EA030742B1 (ru) 2018-09-28
US9845353B2 (en) 2017-12-19
CA2866128C (fr) 2017-02-28
SG11201404491XA (en) 2014-09-26
EP3156073A1 (fr) 2017-04-19
PE20142275A1 (es) 2015-01-08
JP2015510882A (ja) 2015-04-13
US20180057584A1 (en) 2018-03-01
US9376491B2 (en) 2016-06-28
CN104159612A (zh) 2014-11-19
RS55417B1 (sr) 2017-04-28
LT2822590T (lt) 2017-01-25
AU2013230490A1 (en) 2014-08-14
TN2014000341A1 (en) 2015-12-21
EP2822590A1 (fr) 2015-01-14
KR101653082B1 (ko) 2016-08-31
PL2822590T3 (pl) 2017-06-30
HK1199844A1 (en) 2015-07-24
BR112014021308B1 (pt) 2022-08-30
CN104159612B (zh) 2016-03-16
CY1118393T1 (el) 2017-06-28
IL234053A0 (en) 2014-09-30
MA37317A1 (fr) 2016-03-31
EP2822590B1 (fr) 2016-10-26
MX2014010710A (es) 2015-04-14
BR112014021308A2 (pt) 2017-07-04
KR20140120938A (ko) 2014-10-14

Similar Documents

Publication Publication Date Title
MA37317B1 (fr) Formulation d'anticorps il-17
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA46665B1 (fr) Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA31437B1 (fr) Polypeptides, domaines variables d'anticorps et antagonistes
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
WO2018193090A3 (fr) Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
MA38250A1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA34487B1 (fr) Compositions d'anticorps anti-vegfr-3.
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
MA37845B2 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
MA37915A3 (fr) Procedes de traitement d'une tauopathie